Members of Congress are seeking answers to the question of why the United
States was faced with a shortage of vaccines for the 2004-2005 flu season.
Two House and one Senate committee held hearings in November questioning federal
regulators and flu vaccine manufacturer Chiron Corp of Emeryville, Calif,
about the vaccine problem.
Chiron was expected to provide about half of the 100 million doses of
flu vaccine that had been ordered for US residents for the flu season. But
contamination problems at its production plant in England caused British regulators
to suspend the company’s manufacturing license for 3 months, effectively
cutting off the US vaccine supply for this flu season.
Mitka M. Flu Vaccine Probe. JAMA. 2005;293(2):151. doi:10.1001/jama.293.2.151-b
Customize your JAMA Network experience by selecting one or more topics from the list below.